SCHEMBL30584748

SCHEMBL30584748

Cc1ccc(CN2CCC(CNC(=O)N3CCN(c4nc(-c5ccc(OCCO)cc5)no4)CC3)C2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.46
▸ TSHR P16473 2/20 0.46
▸ USP2 O75604 1/20 0.46
▸ S1PR1 P21453 2/20 0.45
▸ MAPT P10636 3/20 0.45
▸ HTT P42858 2/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ TUBB4A P04350 1/20 0.43
▸ TUBB P07437 1/20 0.43
▸ TUBA3C P0DPH7 1/20 0.43
▸ TUBA1B P68363 1/20 0.43
▸ TUBA4A P68366 1/20 0.43
▸ TUBB4B P68371 1/20 0.43
▸ TUBB3 Q13509 1/20 0.43
▸ TUBB2A Q13885 1/20 0.43
▸ TUBB8 Q3ZCM7 1/20 0.43
▸ TUBA3E Q6PEY2 1/20 0.43
▸ TUBA1A Q71U36 1/20 0.43
▸ TUBA1C Q9BQE3 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25402462 1.00 LMNA (0.46) LMNATSHRUSP2S1PR1MAPT
SCHEMBL25401425 0.91 LMNA (0.43) LMNATSHRUSP2S1PR1MAPT
SCHEMBL30584885 0.91 LMNA (0.44) LMNATSHRUSP2S1PR1MAPT
SCHEMBL30584949 0.90 MEN1 (0.49) LMNATSHRUSP2S1PR1MAPT
SCHEMBL25437981 0.82 LMNA (0.59) LMNATSHRMAPTSMN1; SMN2MEN1
SCHEMBL25435838 0.81 MEN1 (0.47) LMNATSHRUSP2MAPTSMN1; SMN2
SCHEMBL30584714 0.81 CCR5 (0.48) LMNATSHRUSP2MAPTSMN1; SMN2
SCHEMBL31546389 0.80 MAPT (0.57) LMNAMAPTHTTNPC1SMN1; SMN2
SCHEMBL25433137 0.79 CCR5 (0.53) LMNATSHRUSP2MAPTNPC1
SCHEMBL30584823 0.78 ACHE (0.51) LMNATSHRUSP2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 — — US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 — — US disclosed
EP-4463452-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2024-11-20 — — EP disclosed
WO-2023177700-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2023-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 LMNA 1344/4885TSHR 4347/4885USP2 2798/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 LMNA 1344/4885TSHR 4347/4885USP2 2798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback